- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about VTRS
Recent news which mentions VTRS
From Benzinga
From Benzinga
Regeneron Celebrates Legal Win: Court Upholds Eylea Medication Patent
December 28, 2023
From Benzinga
3 Minutes To Boost Your Earnings: 3 Stocks With Over 3% Dividend Yields In Health Care Sector From Wall Street's Most Accurate Analysts
December 27, 2023
From Benzinga
A Look Into Healthcare Sector Value Stocks
December 25, 2023
From Benzinga
From MarketWatch
Buy Alert: Analysts Say These 3 Growth Stocks Could Double in 2024
November 30, 2023
From InvestorPlace
7 Low P/E Stocks Poised to Rebound
November 20, 2023
From InvestorPlace
5 Value Stocks To Watch In The Healthcare Sector
November 13, 2023
From Benzinga
3 Large-Cap Stocks to Buy Trading Below Book Value
November 07, 2023
From InvestorPlace
Earnings Scheduled For November 7, 2023
November 07, 2023
From Benzinga
Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?
October 31, 2023
From Motley Fool
Viatris Just Sold Off 3 Key Segments. Is It Still a Buy?
October 13, 2023
Tickers
VTRS
From Motley Fool
2 Top Value Stocks to Buy in October
October 08, 2023
From Motley Fool
2 Healthcare Dividend Stocks You'd Regret Not Buying on the Dip
October 08, 2023
From Motley Fool
Viatris makes progress on Ozempic patent challenge
October 04, 2023
From MarketWatch
Obesity Drug Wegovy's Triumph to Catapult Novo Holdings In Golden Era Of Wealth Boost
October 03, 2023
From Benzinga
From Benzinga
From Benzinga
Viatris Phase 1 Asset Divestiture Story: Plans To Sell Certain OTC Products, Women's Healthcare Business & More
October 02, 2023
Tickers
VTRS
From Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
September 27, 2023
From Benzinga
Despite Efforts, Vulnerable Patients Still Face Barriers to Essential Medicines, Says New Report
September 26, 2023
From Benzinga
'Stocks In Monopolistic Bull Market': Wall Street Analyst Contemplates A Bright Future For Next Phase
September 22, 2023
From Benzinga
From Motley Fool
3 Pharmaceutical Stocks That Are Too Cheap to Ignore
September 09, 2023
From Motley Fool
From MarketWatch
From Motley Fool
Stock market bulls are still on top
August 31, 2023
From MarketWatch
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.